Outcome of children with high-risk acute myeloid leukemia given autologous or allogeneic hematopoietic cell transplantation in the aieop AML-2002/01 study
| Autor: | Andrea Pession, Sergio Rutella, Arcangelo Prete, Edoardo Lanino, Ottavio Ziino, Franca Fagioli, Giovanna Giorgiani, Chiara Messina, Attilio Rovelli, Claudio Favre, Franco Locatelli, Giuseppe Palumbo, Mimmo Ripaldi, Riccardo Masetti, Marco Zecca, Marta Pillon, Alice Bertaina, Roberto Rondelli |
|---|---|
| Přispěvatelé: | Locatelli, F., Masetti, R., Rondelli, R., Zecca, M., Fagioli, F., Rovelli, A., Messina, C., Lanino, E., Bertaina, A., Favre, C., Giorgiani, G., Ripaldi, M., Ziino, O., Palumbo, G., Pillon, M., Pession, A., Rutella, S., Prete, A. |
| Jazyk: | angličtina |
| Rok vydání: | 2015 |
| Předmět: |
Oncology
Myeloid Male Transplantation Conditioning medicine.medical_treatment Abnormal Karyotype Hematopoietic stem cell transplantation chemotherapy conditioning regimen bone-marrow-transplantation Allograft AML immune system diseases hemic and lymphatic diseases Autografts Child total-body irradiation acute lymphoblastic-leukemia versus-host-disease competing risks cord blood donor aml Leukemia Medicine (all) Hematopoietic Stem Cell Transplantation Hematology Allografts Survival Rate Leukemia Myeloid Acute surgical procedures operative medicine.anatomical_structure Cord blood Child Preschool Female Cord Blood Stem Cell Transplantation Human medicine.drug medicine.medical_specialty Adolescent Disease-Free Survival Follow-Up Studies Humans Infant Myeloablative Agonists fms-Like Tyrosine Kinase 3 Transplantation chemical and pharmacologic phenomena Acute Myeloablative Agonist Follow-Up Studie Internal medicine Autograft medicine Preschool Settore MED/38 - Pediatria Generale e Specialistica business.industry medicine.disease Surgery Graft-versus-host disease business Busulfan |
| Popis: | We analyzed the outcome of 243 children with high-risk (HR) AML in first CR1 enrolled in the AIEOP-2002/01 protocol, who were given either allogeneic (ALLO; n=141) or autologous (AUTO; n=102) hematopoietic SCT (HSCT), depending on the availability of a HLA-compatible sibling. Infants, patients with AML-M7, or complex karyotype or those with FLT3-ITD, were eligible to be transplanted also from alternative donors. All patients received a myeloablative regimen combining busulfan, cyclophosphamide and melphalan; [corrected] AUTO-HSCT patients received BM cells in most cases, while in children given ALLO-HSCT stem cell source was BM in 96, peripheral blood in 19 and cord blood in 26. With a median follow-up of 57 months (range 12-130), the probability of disease-free survival (DFS) was 73% and 63% in patients given either ALLO- or AUTO-HSCT, respectively (P=NS). Although the cumulative incidence (CI) of relapse was lower in ALLO- than in AUTO-HSCT recipients (17% vs 28%, respectively; P=0.043), the CI of TRM was 7% in both groups. Patients transplanted with unrelated donor cord blood had a remarkable 92.3% 8-year DFS probability. Altogether, these data confirm that HSCT is a suitable option for preventing leukemia recurrence in HR children with CR1 AML. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|